



Applied Biosystems
An Applera Corporation Business
850 Lincoln Centre Drive
Foster City, CA 94404-1128 U.S.A.
www.appliedbiosystems.com

FAX TRANSMITTAL

Date: March 11, 2005

To: Issue Fee
U.S. Patent and Trademark Office
Commissioner for Patents

Fax No.: 703-746-4000
Phone No.: 703-305-8283

From: Deborah Mojarro for Andrew K. Finn, Reg. No. 54,097
Legal Department
Fax No.: 650-638-6677
Telephone No.: 650-554-3425
Email: mojarrrda@applera.com

Subject: Issue Fee and Publication Fee Transmittal
U.S. Patent Application No. 10/099,738
Filing Date: March 15, 2002
In re Application of: CHRISTIAN A. HEID et al.
Title: METHODS FOR EXTERNAL CONTROLS FOR NUCLEIC ACID
AMPLIFICATION

Our File: 4498 C1 US

No. of pages (including cover sheet): 7

Enclosures:


Issue Fee and Publication Fee Transmittal (1 page in duplicate);
Part B - Fee(s) Transmittal (PTOL-85) (1 page in duplicate); and
Comments on Statement of Reasons for Allowance (2 pages)

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 703-746-4000 on March 11, 2005.

Deborah A. Mojarro
Name


Signature

Note: The information contained in this facsimile message may be attorney-client privileged and may contain confidential information intended only for the use of the individual named above, and others who have been specifically authorized to receive it. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify me immediately by telephone (650) 638-6464 and return the original transmission to me by mail without making a copy. Thank you.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

CHRISTIAN A. HEID et al.

Serial No.: 10/099,738

Filed: March 15, 2002

For: **EXTERNAL CONTROL
REAGENTS FOR NUCLEIC
ACID AMPLIFICATION**

Confirmation Number: 5560

) Group Art Unit: 1637

) Examiner: JOYCE TUNG

) Allowed: December 21, 2004

CERTIFICATE OF MAILING Under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with
the United States Postal Service as First Class Mail addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA
22313-1450 on

March 11, 2005

(Date of Deposit)

Deborah A. Majano

Name of Depositing Party

Signature of Depositing Party

COMMENTS ON STATEMENT OF REASONS FOR ALLOWANCE

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Examiner's Reasons for Allowance mailed with the Notice of Allowance on December 12, 2004, Applicants thank the Examiner for allowing claims 1-31 of the instant case. For the sake of additional clarity, applicants wish to address two issues.

As a first matter, Applicants agree with the Examiner's Reasons for Allowance mailed December 21, 2004, including the indication that "Concerning claims 1-31, no prior art has been found teaching or suggesting the kit for nucleic acid amplification comprising a single stranded external control polynucleotide, a forward primer, a reverse primer and a detectable probe wherein the forward primer and the detectable probe are separated by 0-5 nucleotides when hybridized to the external control polynucleotide, and the reverse primer and the detectable probe are separated by 0-5 nucleotides when hybridized to the external control polynucleotide. The closest prior art is the reference of Aoyagi et al. (5952202, issued September 14, 1999)..."

Appl. No. 10/099,738
Filed March 15, 2002

4498 CI US


In an earlier correspondence on August 30, 2004, applicants indicated that arguments made on May 6, 2003 remained in effect, specifically "applicants pointed out that their claimed invention, unlike Aoyagi, teaches the following element of claim 1 of the instant application, "wherein the forward primer and the detectable probe are separated by 0 to 5 nucleotides when hybridized to the external control polynucleotide, or its complement, and the reverse primer and the detectable probe are separated by 0 to 5 nucleotides when hybridized to the external control polynucleotide, or its complement." Applicants further noted on August 30, 2004, that additionally, 103(c) could be invoked, given the obligation of applicants to assign to the same entity as Aoyagi. However, in light of the Examiner's Reason for Allowance, and solely for the reasons of expediting allowance and minimizing unnecessary correspondence, applicants no longer consider it necessary to pursue this argument and its corresponding evidentiary support.

As a second matter, in the Notice of Allowability sent December 7, 2004, the Examiner indicates that "The drawings filed on 15 March 2004" are accepted by the Examiner." Applicants wish to note that no drawings were filed on 15 March 2004. Applicants presume that Examiner's statement pertains to the drawings filed with the application on March 15, 2002.

Applicants again thank the Examiner for allowing claims 1-31 of the instant case. An issue fee is hereby enclosed.

Respectfully submitted,

Date: 3-11-05


Andrew K. Finn, Reg. No. 54,097
Agent for Applicants

CORRESPONDENCE ADDRESS

Customer Number 22896
Applied Biosystems
850 Lincoln Centre Drive M/S 432-2
Foster City, California 94404
TEL: 650-570-6667
FAX: 650-638-6677